Relay Therapeutics (RLAY) said Wednesday it priced a public offering of 22.9 million common shares at $12 each.
The agreement grants underwriters a 30-day window to acquire up to 3.4 million additional shares, and the stock sale is projected to raise about $275 million in gross proceeds, the company said.
Shares of the company were down 1% in Wednesday premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments